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 Providing the DiRECT/Counterweight-Plus intervention in primary care incurs a cost 20 
(£2,359 per one-year diabetes remission) below the average annual direct cost of 21 
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potential for long-term cost effectiveness 23 
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 Providing a reasonable proportion of remissions can be maintained for a period of time, 25 
with multiple medical gains expected, as well as immediate social benefits, there is a 26 
case for shifting resources within diabetes care budgets to offer support for people with 27 
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Abstract  1 
 2 
Background: The Counterweight-Plus weight management programme achieved 46% 3 
remissions of type 2 diabetes at one year in the DiRECT trial. We estimated the 4 
implementation costs of the Counterweight-Plus programme and its one-year cost-5 
effectiveness in terms of diabetes remission, compared with usual care, from the UK NHS 6 
perspective. 7 
Methods: Within-trial total costs included the programme set-up and running cost (practitioner 8 
appointment visits, low formula diet sachets, and training), oral anti-diabetes and 9 
antihypertensive medications, and healthcare contacts. Total costs were calculated for 10 
aggregated resource use for each participant and 95% confidence intervals were based on 11 
1,000 non-parametric bootstrap iterations. 12 
Findings: One-year programme cost under trial conditions was estimated at £1,137 per 13 
participant (95%CI £1,071, £1,205). The intervention led to a significant cost-saving of £120 14 
(95%CI £78, £163) for the oral anti-diabetes drugs and a £14 (95%CI £7.9, £22) saving for 15 
antihypertensive medications compared to the control. Deducting the cost-savings of all 16 
healthcare contacts from the intervention cost resulted an incremental cost of £982 (95%CI 17 
£732, £1,258). Cost per one-year diabetes remission was £2,359 (95%CI £1,668, £3,250). 18 
Interpretation: Remission of type 2 diabetes within one-year can be achieved at a cost lower 19 
than the annual cost of diabetes (including complications). Providing a reasonable proportion 20 
of remissions can be maintained for a period of time, with multiple medical gains expected, as 21 
well as immediate social benefits, there is a case for shifting resources within diabetes care 22 
budgets to offer support for people with type 2 diabetes to attempt remission. 23 
 24 





Approximately one in 12 adults worldwide have type 2 diabetes [1]. Care for people with 2 
diabetes accounts for 24% of total healthcare spending in the USA, with more than half directly 3 
attributable to diabetes (approximately USD$9,600 per diagnosed person per year) [2]. These 4 
figures are expected to rise rapidly with increasing prevalence of type 2 diabetes and the 5 
introduction of new more expensive treatment options. Diabetes accounted for approximately 6 
10% of the total UK NHS budget (£8.8 billion in 2010/2011), with 80% attributed to diabetes 7 
complications. This is anticipated to rise to 17% (£22 billion) by 2035, if traditional approaches 8 
to diabetes management continue [3]. Indirect costs (economic output lost), were even greater, 9 
at £13 billion, largely through working years lost (including early mortality), and the burden of 10 
informal care required for people with diabetes aged over 70 years. In Germany, annual direct 11 
healthcare cost was increased 1.8-fold with diabetes (€3,352 vs €1,849), and indirect costs 12 
elevated two-fold (€4,103 vs €1,981) compared to those without diabetes [4]. 13 
Type 2 diabetes is being diagnosed younger as populations become more overweight, and 14 
expensive complications are much more likely with a younger diagnosis [5]. A US study 15 
estimated lifetime medical spending at US$35,900 for people who were diagnosed with 16 
diabetes at age 65 years but US$124,600 with diagnosis aged 40 years [6]. This suggests that 17 
periods of diabetes remission may be particularly valuable for younger people with diabetes, 18 
avoiding enormous expenditure. 19 
Current guidelines for type 2 diabetes management focus heavily on drug treatments to lower 20 
blood glucose and counter elevated cardiovascular risks. These management strategies, 21 
however, are not aimed at remission of diabetes, which progresses, so morbidity and mortality 22 
remain high despite the application of clinical guidelines [7]. Bariatric surgery can consistently 23 
convert 60-80% of people with type 2 diabetes to a non-diabetic state for 2-5 years, through 24 
weight loss >10-15kg [8]. Surgical treatments present their own risks and long-term 25 
complications, and reach only 1% of the eligible population [9], and are less preferred by 26 
people [10], so other options are needed. Several studies have found weight loss of this order 27 
from non-surgical calorie restriction and structured weight-loss maintenance can normalize 28 
hepatic fat, blood glucose and insulin, and may extend life expectancy for people with type 2 29 
diabetes [11-13].  30 
The Diabetes Remission Clinical Trial (DiRECT) assesses the extent to which effective weight 31 
management, delivered in the primary care setting, can lead to sustained remission of type 2 32 
diabetes [14,15]. DiRECT is an open-label, cluster-randomised trial in 49 primary care 33 
practices, which represented the characteristics of people with diabetes and poorer social 34 
settings where type 2 diabetes is most frequent in Scotland and the Tyneside region of 35 
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England. Eligibility criteria included age 20-65 years, type 2 diabetes diagnosed within the 1 
previous six years, body-mass index (BMI) 27-45 kg/m2, and most recent HbA1c >48mmol/mol 2 
(6.5%) (or >43 mmol/mol (6.1%) if taking diabetes medication). Between July 2014 and Aug 3 
2016, 298 participants were randomised equally to control (usual care) and intervention 4 
groups. Both groups continued to receive optimal routine care under current clinical guidelines. 5 
Participants in the intervention arm followed the Counterweight-Plus weight management 6 
programme, to achieve and maintain substantial weight loss, aiming for >15kg weight loss. 7 
The programme, delivered in the primary care setting by trained dietitians or practice nurses, 8 
contained three phases: ‘total diet replacement’ during which participants consumed only a 9 
low energy formula diet (soups and shakes, 825–853 kcal/day) for 12 weeks, which could be 10 
extended up to 20 weeks to accommodate holidays or other periods of slow progress, followed 11 
by a structured food reintroduction phase of 2-8 weeks, and then longer-term weight loss 12 
maintenance. Following weight loss, ‘rescue packages’ of the formula diet may be provided 13 
if >2kg weight was regained or diabetes returned. All oral anti-diabetes and antihypertensive 14 
medications were ceased, on safety grounds, when participants began the programme. These 15 
were reintroduced under standard protocols following national clinical guidelines, where 16 
indicated by regular monitoring of blood glucose and blood pressure. Otherwise, participants 17 
in both groups continued to receive diabetes care under current national guidelines and 18 
standards. At one year, DiRECT showed remission of diabetes (HbA1c < 48 mmol/mol (6.5%)) 19 
was achieved in 46% of intervention and 4% of control participants (p<0.0001) [15]. We have 20 
previously briefly reported the intervention cost and cost per diabetes remission [16] and now 21 
report the methods used in detail, especially the Counterweight-Plus programme cost 22 
elements, and the complete results of the one-year within-trial cost-effectiveness analysis. 23 
 24 
Methods 25 
This analysis adopted the perspective of the UK National Health Service (NHS). Cost per 26 
additional diabetes remission at one year (2016/2017 prices) is calculated from the resource 27 
use and the proportion of diabetic remissions observed from the Counterweight-Plus and 28 
usual-care arms in DiRECT, based on the intention to treat (ITT) principle.  29 
 30 
DiRECT intervention set-up cost 31 
Fixed costs of providing the Counterweight-Plus intervention include ‘set-up’ costs for training 32 
practitioners (nurse or dietitian). Each practitioner received structured training by experienced 33 
7 
 
Counterweight-Plus research dietitians. This totalled 16 hours of face-to-face sessions (one 1 
initial eight-hour session plus one four-hour session for weight loss maintenance and a further 2 
four-hour consolidation session). Training is required for one practitioner per participating 3 
practice, though several practitioners may undergo training in groups. Costs associated with 4 
the training included practitioners’ attendance time and instructors’ costs, based on a £300 5 
Counterweight-Plus fee (paid per practitioner), that also includes provision of dedicated 6 
training materials, and annual licence fee which covers Counterweight-Plus programme 7 
support and access to a medical advisor. After training practitioners, Counterweight-Plus 8 
research dietitians provide mentoring support for them when they see their first few 9 
intervention participants, with standard competency checks and fidelity testing. This service is 10 
included in the £300 Counterweight-Plus fee.  11 
We costed practitioner time using standard UK unit cost sources (Personal Social Service 12 
Research Unit (PSSRU)). Training costs were annualised, assuming each trained practitioner 13 
remains in place for five years.  14 
 15 
DIRECT intervention running cost 16 
Resource use for running the Counterweight-Plus weight management intervention included 17 
the formula diet (total diet replacement sachets), review appointments with a practitioner, and 18 
supporting workbooks. The number of sachets issued to each participant and duration of each 19 
appointment were collected prospectively throughout the study. 20 
Sachets of low energy formula-diet (reconstituted with water as soups and shakes, 4 sachets 21 
daily) are designed to supply all essential micronutrients. Sachets were intended to replace all 22 
food during total diet replacement. During the food reintroduction phase, food-based diet 23 
gradually replaced the low energy sachets. Occasional further use of sachets, however, was 24 
permitted during the weight loss maintenance stage. Participants attended fortnightly review 25 
appointments during total diet replacement and food reintroduction stages, and monthly 26 
appointments during weight loss maintenance. Actual consumption of sachets and 27 
attendances for healthcare appointments were included in the cost analysis; these varied 28 
across participants, depending, for example, on adherence, holidays, time to weight loss, and 29 
need for ‘rescue plans’. The workbooks were provided to participants at the start of each of 30 
the phases but were included in full in the cost analysis for each enrolled participant 31 
irrespective of potential drop-out [14]. Details of the programme have been described 32 




Health care contacts and medication use 1 
Data on all contacts with medical professionals in primary and secondary care were obtained 2 
directly from the GP practice records. This ensured the completeness and accuracy of the 3 
resource use data, including for those who ceased to engage with the intervention. This 4 
method did not depend on self-reporting, and thus avoiding recall bias. Each primary or 5 
community care record was indicated as being related to diabetes or otherwise. Unit costs for 6 
health care resource use, including medical contacts and hospitalisations, were obtained from 7 
published national sources (PSSRU, NHS reference costs, or Information Services Division 8 
(ISD) Scotland) for the 2016-2017 financial year (Appendix 1). 9 
Use of oral anti-diabetes and antihypertensive medicines was suspended on initiation of the 10 
programme and reinstated as necessary according to NHS clinical guidelines, however, 11 
people who achieve and sustain remission, may continue without these medications. Use of 12 
these medications was costed according to individual participants’ medication records in each 13 
participating GP practice. Data included dose, frequency, start and end dates of each 14 
medication. Prescriptions for all concomitant medications (i.e., other than the oral anti-15 
diabetes and antihypertensive medications) were compared between arms but were not 16 
included in our cost estimates. Unit cost for individual doses of each medication was calculated 17 
based on the British National Formulary online database (accessed June 2018).  18 
 19 
Statistical analysis 20 
Statistical analysis was conducted according to the intention to treat (ITT) principle with all 21 
randomised participants included in the analysis. Patient characteristics have been previously 22 
reported elsewhere [15]. Resource use data were incomplete for one participant in each arm 23 
(< 1%) due to relocation. For the one relocated participant in the control arm, we assumed 24 
that she/he continued oral anti-diabetes or antihypertensive drugs throughout the period. The 25 
relocated intervention group participant attended only one intervention visit, so we also 26 
assumed continued usage in that case. We assigned each of these participants zero 27 
healthcare contacts. Mean cost was calculated by averaging the aggregated resource use 28 
costs (Counterweight-Plus intervention, primary and secondary care, oral anti-diabetes and 29 
antihypertensive medication) over all participants within each group. Standard errors of all 30 
analyses were adjusted for clustering at GP practice level. An incremental cost effectiveness 31 
ratio was calculated as the difference in the groups’ total costs divided by the difference in 32 
diabetes remission rates at one-year. 95% confidence intervals were based on 1,000 non-33 
parametric bootstrap iterations (samples with replacement from the observed data). All 34 




Intervention cost 2 
The total cost per intervention participant of delivering the Counterweight-Plus programme 3 
was £1,137 (95% CI: £1,071, £1,205) (Table 1). The mean duration of total diet replacement, 4 
food reintroduction and weight loss maintenance was 3.5, 2.3 and 3.5 months respectively, 5 
including all participants who ceased the intervention. Each participant consumed a mean of 6 
3.6, 0.9 and 0.5 sachets per day and attended 2.2, 1.6 and 1.2 appointments per month for 7 
total diet replacement, food reintroduction and weight loss maintenance respectively (Figure 8 
1). In total, each participant was issued a mean of 495 sachets (costed at £708), which 9 
accounted for over half of total intervention costs. A total of 15.6 (95% CI: 14.7, 16.5) 10 
practitioner visits (costed at £362) were observed over the first year, and these accounted for 11 
approximately one third of total intervention costs.  12 
 13 
Routine resource use and cost over one-year 14 
Table 2 shows the healthcare contacts of participants over the 12-month period. There was 15 
little difference between the arms, as might be expected, though participants in the intervention 16 
arm had fewer GP visits related to diabetes (mean difference 0.5; 95% CI: 0.2, 0.7), and fewer 17 
practice nurse visits unrelated to diabetes (0.5; 95% CI: 0.1, 1.0). The aggregate number of 18 
days using individual oral anti-diabetes and antihypertensive drugs, however, differed greatly 19 
between arms with the intervention arm having a total of 332 fewer days per participant on 20 
oral anti-diabetes medications and 240 fewer days on antihypertensive drugs. 21 
Table 3 applies unit costs to the resource use. Overall, the intervention group’s costs for 22 
routine healthcare contacts were £155 (95% CI: -£74, £394) lower than the control group’s. 23 
Statistically significant mean differences were observed for oral anti-diabetes drugs of £120 24 
(95% CI: £78, £163) per participant, and for antihypertensive drugs of £14 (95% CI: £7.9, £22). 25 
Aggregating the intervention costs and routine resource use costs together, the difference in 26 
total costs over one-year between the groups was therefore due almost entirely to the 27 
intervention delivery cost, with some offset provided through medication cost savings.  28 
 29 
Cost-effectiveness for remission of diabetes 30 
Over the one-year period, the mean cost per participant was £1,827 (95% CI £1,652, £2,021) 31 
in the intervention group and £846 (95% CI £685, £1,038) in the control group (Table 4), 32 
leading to an incremental cost difference of £982 (95% CI £732, £1,258) per participant. 33 
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Combined with the incremental remission rate (42%; 95% CI 33%, 50%), the incremental cost 1 
per diabetes remission over the first year was £2,359 (95% CI £1,668, £3,250). 2 
Discussion 3 
We have analysed the observed resource use over one year, under the DiRECT trial 4 
conditions, to estimate the DIRECT/Counterweight-Plus intervention cost and its cost-5 
effectiveness (incremental cost per remission achieved). The average cost of intervention 6 
delivery was £1,137 per participant randomised to the intervention arm. There were observed 7 
reductions in several routine (non-intervention) cost elements such that the net intervention 8 
cost per participant was £982. The intervention delivery costs may be reduced when rolled out 9 
in routine practice. For example, the training costs per participant, with an average of five 10 
participants per practice in the trial (33 practitioners managing 149 participants), will be lower 11 
as each trained practitioner will manage many more people. Lower costs of formula diet 12 
sachets per participant in the programme would be expected in routine practice if lower unit 13 
costs could be negotiated for large contracts. As patients following the Counterweight-Plus 14 
programme do not require normal food during total diet replacement, and less than usual 15 
during the food re-introduction and maintenance stages, there will be some decreased spend 16 
for patients.  A case might be made to introduce out-of-pocket payment for the formula diet 17 
sachets. This could apply after a specific period, be part payment, or for ongoing use such as 18 
rescue plans or for one sachet per day for weight loss maintenance. For people in some socio-19 
economic groups there may be value in exploring means tested payments to avoid widening 20 
the inequality gap in this area of care. Such options would need careful consideration and 21 
ongoing audit to ensure no impact on effectiveness.  22 
The delivery cost of the DiRECT/Counterweight-Plus programme compares favourably with 23 
other diabetes remission interventions. There are no directly comparable studies of weight 24 
management with diabetes remission as the primary outcome. The US Look AHEAD trial in 25 
type 2 diabetes involved an exercise training and weight loss intervention which cost almost 26 
twice as much the DiRECT intervention (USD $2,865 per participant, 2012 value), but DiRECT 27 
achieved greater weight losses and a four-fold greater remission rate at 1 year (DiRECT 46% 28 
vs. Look AHEAD 12%) [17,18]. Bariatric surgery usually produces much greater weight losses 29 
and remissions of type 2 diabetes, however, surgery carries risks of mild to serious long-term 30 
complications, with frequent vitamin and mineral deficiencies and symptoms such as 31 
hypoglycaemia and hypovolemic dumping, and it is expensive (e.g., at £6,346 [19] for 32 
laparoscopic gastric bypass, £7,224 (€8,105 [20]) for vertical banded gastroplasty), with most 33 
costs incurred during the initial hospitalisation [21]. 34 
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Limited offsetting cost-savings were observed in the initial 12-months (including significantly 1 
lower prescription costs). The benefits from weight loss and remission may persist into future 2 
years during which the relatively high initial intervention costs do not apply. The two-year 3 
analysis will inform this. The numbers of participants prescribed any concomitant medication 4 
during the study (i.e., excluding oral anti-diabetes, diuretic and antihypertensive drugs) were 5 
comparable between the arms. Given this, the low cost of most items, and the likelihood that 6 
any aggregate differences would tend to favour the intervention arm through the broader 7 
benefits related to weight loss, we excluded the concomitant medications from the present 8 
analysis. However the proportion of participants taking no prescription drugs increased in the 9 
intervention arm at 12 months in DiRECT [15], pointing to further possible cost advantages for 10 
the intervention in the longer term.  11 
 12 
Strengths and Limitations  13 
This analysis is based on one-year outcomes, and detailed data collection, during a rigorously 14 
conducted randomised trial. DiRECT was the first study in a primary care setting to set 15 
remission of type 2 diabetes as a primary outcome. The intervention was well received by 16 
participants, with significantly improved quality of life at one year, and healthcare contacts 17 
outside the trial were reduced (e.g. GP visits as shown in the results). The participants were 18 
very typical of people currently living with type 2 diabetes, up to 6 years after diagnosis. A high 19 
proportion were from socially deprived circumstances, where type 2 diabetes is most prevalent 20 
and difficult to manage [22]. The study design ensured that cost and outcome data were 21 
available from primary care records in nearly all the participants (296/298 for costs and 22 
298/298 for remission rates) for ITT analysis, even if they had ceased to engage with the 23 
programme. The control group received standard treatment under guidelines which are 24 
broadly similar internationally. Our results are thus likely to be robust and generalizable. 25 
The costs of the intervention, and of routine care, are similar in many other studies [23,24]. 26 
For example, the standard care arm among people with prediabetes in the UK Let’s Prevent 27 
trial had an annual mean non-inpatient health service cost of £437 and medication cost of 28 
£124 [24], which is similar to the control arm resource use in our study (£520 for non-inpatient 29 
health care services, and £168 for primary medications as shown in Table 3). As such the 30 
present economic analysis is likely to be widely transferable to diabetes care elsewhere, at 31 
least within countries with similar healthcare systems. However, the population studied was 32 
almost entirely European, and up to six years after diagnosis: we cannot be certain whether 33 
the results are applicable to people from other racial or ethnic origins where type 2 diabetes 34 
has different characteristics, or with diabetes for over six years. Asian populations have a 35 
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higher prevalence of diabetes than their European counterparts for the same BMI [25]. Also, 1 
many Asian people with diabetes develop both early β cell dysfunction and insulin resistance, 2 
so many require earlier insulin treatment [26]. There is therefore need for research to evaluate 3 
intensive weight management in Asian populations and to develop appropriate methods for 4 
developing countries, where type 2 diabetes and its treatment costs are rising dramatically. 5 
Future long-term cost-effectiveness analysis 6 
Over a period of one year, it would be unrealistic to expect to identify resource savings relating 7 
to the long-term consequences of diabetes, such as neuropathy, renal failure and vison loss, 8 
and DiRECT was not powered for these outcomes. Nevertheless, given the clear benefit of 9 
lower HbA1c in reducing complications [27], diabetes remission rates such as those seen in 10 
DiRECT at one-year are potentially transformative both for participants’ health, quality of life, 11 
and longevity, and for the burden to healthcare systems such as the NHS. Participants’ 12 
abilities to maintain weight loss and healthy lifestyles, and avoid reversion to a diabetic state 13 
will be critical but are under-researched, and will require appropriate research and 14 
development investment for programme improvement. There is ample evidence that 15 
substantial weight loss and a period of remission consistently improves multiple cardio-16 
metabolic risk factors [28,29], and that weight management interventions may extend life 17 
expectancy [12]. On-going follow up in DiRECT will contribute to modelling of long-term health 18 
gains, resource savings following initial remission, and inform long-term cost-effectiveness 19 
modelling and healthcare planning. Recent studies using different methodologies have 20 
indicated reduced life expectancy with type 2 diabetes of 6 - 7 years for those who are 21 
diagnosed with diabetes at the age of 50 years (similar to DiRECT population) [7,30,31]. 22 
Irrespective of future resource use that may be avoided, such estimates imply costs per 23 
quality-adjusted life-year (QALY) ratios comfortably within the cost-effectiveness threshold of 24 
£20,000 - £30,000 per QALY gained applied to healthcare interventions in the UK. 25 
Conclusions 26 
Providing the DiRECT/Counterweight-Plus intervention in primary care incurs a cost lower 27 
than the average annual direct cost of managing a person with type 2 diabetes (including 28 
complications at later stage), and has the potential for long-term cost effectiveness, based on 29 
the data up to one year. The programme involves early intervention costs that may generate 30 
substantial future healthcare resource savings if remissions and reduced drug prescriptions 31 
are maintained by sufficient numbers of participants. DiRECT is on-going, and further data will 32 
support future cost-effectiveness analyses incorporating long-term outcomes including quality-33 
adjusted life-years. However, given the likelihood that a period of remission will reduce 34 
13 
 
disabling long-term diabetes complications, as well as improving quality of life, the case 1 
already appears strong for shifting resources within diabetes care budgets to offer the support 2 
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Tables and figures 
Table 1 Intervention resource use components and cost (per participant) (n=149) over the first 12 months of the DiRECT trial 
Intervention cost components      Total 
1a. Intervention set-up cost Units Unit cost   
Counterweight-Plus specialist training, support 
and mentoring  
33 practitioners £300 per practitioner  £9,900 
Practice nurses and dieticians’ time  16 hours per practitioner £42 per hour c  £22,176 
Total set-up cost      £32,076 
Total set-up cost annualised over five years a      £7,104 
Total intervention set-up cost per participant      £48e 
       
1b. Intervention running resource use and costs 

















Total (95% CI) 
Intervention running resource use Mean (SD) (n=149b)  
Number of practice nurse or dietician visits 7.7 (2.9) 3.7 (1.9) 3.5 (2.7) 0.3 (0.7) 0.4 (1.0) 15.6 (14.7, 16.5) 
Number of Counterweight-Plus sachets issued 383 (156) 62 (50)  30 (48) 10 (27) 10 (31) 495 (461, 530) 
Intervention running cost Mean (SD) (n=149b) (£)  
Practice nurse/dietitian visits c 172 (63) 88 (47) 84 (63) 7.7 (19) 10 (24) £362 (337, 384) 
Sachets c 547 (223) 89 (71) 42 (68) 14 (39) 15 (44) £708 (659, 757) 
Counterweight-Plus booklets      £20 (-) 
Total intervention running cost per participant      £1,089 (1,023, 1,158) 
        
Total cost per participant (n=149)      £1,137 (1,071, 1,205) 
a. Annualising the total cost over five years using the formula, equivalent annual cost (E): =K/[(1-1/(1+r)n)/r]. K=£32,076, r=3.5%, n=5, gives an annual specialist training and 
support cost of £48 per participant. 
b. Includes six randomised participants who did not initiate the intervention. 
c. Unit cost £42/hour was obtained from the PSSRU unit cost of medical and social care 2016/2017; sachet costs £20 per 14 sachets. 
d. 95% CI was obtained from 1000 iterations of bootstrap. 
e. This is the training cost for 33 practitioners managing 149 participants (a ratio of 1:4.5), as implemented in the trial.
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Table 2 NHS resource use quantity per participant 12 months trial period 
Resource use items a 
Mean (SD) 
Mean difference   









GP 0.44 (0.82) 0.89 (1.24) -0.45 (-0.69, -0.20) 
Practice nurse 1.73 (1.41) 2.03 (1.52) -0.30 (-0.64, 0.03) 
Health care assistant 0.26 (0.64) 0.32 (0.72) -0.07 (-0.23, 0.09) 
Community care 0.41 (0.67) 0.43 (0.87) -0.02 (-0.21, 0.15) 
Primary care visits not related to diabetes    
GP 3.91 (4.71) 4.05 (4.70) -0.14 (-1.24, 0.95) 
Practice nurse 0.94 (1.53) 1.46 (2.74) -0.52 (-1.03, -0.07) 
Health care assistant 0.16 (0.48) 0.28 (1.54) -0.11 (-0.41, 0.09) 
Community care 0.28 (0.90) 0.28 (1.75) -0.00 (-0.38, 0.27) 
Outpatient visits 1.31 (1.90) 1.81 (2.72) -0.50 (-1.02, 0.03) 
Hospitalisation length of stay (day) 0.21 (0.98) 0.17 (0.72) 0.03 (-0.16, 0.24) 
Medication days (sum of individual drug days) d    
Oral anti-diabetes drugs 104 (197) 436 (312) -332 (-397, -267) 
Antihypertensive drugs 148 (218) 387 (389) -240 (-314, -166) 
a. The resource use included all the health care contacts the participants had over the one-year period 
except for the intervention visits, including the routine annual checks for diabetes such as retina 
screening for both arms. 
b. Included one participant in each arm who moved away from the trial participating practice. Their 
healthcare resource use was assumed to be 0 after they moved away, and their medication use was 
assumed to continue since they moved away. 
c. 95% CI for the mean differences were obtained from bootstrap.  
d. The number of ‘individual-drug-days’ was generated by adding together the number of days on each 
individual drug taken by participants during the one-year period. If the participant has more than one oral 
anti-diabetes medication administered during the one-year period, then the days were added up 




Table 3 NHS cost (£) per participant (n=149 for each arm) over the 12 months trial period 
 Cost (per participant) 
Mean cost (SD) (£) Mean difference 
(Intervention – 





3a. Resource use of health care contacts    
Primary and community care visits related to 
diabetes 
   
GP 17 (31) 34 (47) -17 (-26, -7.6) 
Practice nurse 19 (15) 22 (16) -3.3 (-7.0, 0.3) 
Health care assistant 1.0 (2.6) 1.3 (2.9) -0.3 (-0.9, 0.4) 
Community care 16 (28) 18 (43) -2.2 (-11, 5.6) 
Primary and community care visits not related 
to diabetes 
   
GP 149 (179) 154 (178) -5.4 (-47, 36) 
Practice nurse 10 (17) 16 (30) -5.6 (-11, -0.8) 
Health care assistant 0.6 (1.9) 1.1 (6.2) -0.5 (-1.6, 0.4) 
Community care 13 (45) 13 (92) -0.2 (-20, 14) 
Outpatient visits 244 (476) 261 (407) -17 (-111, 83) 
Hospitalisation 187 (796) 157 (713) 30 (-142, 201) 
Total cost of resource use of health care 
contacts 
656 (1,047) 677 (1,028) -21 (-249, 215) 
    
3b. Medications    
Anti-diabetes drugs 29 (86) 149 (228) -120 (-163, -78) 
Antihypertensive drugs 5.3 (9.1) 19 (43) -14 (-22, -7.9) 
Total cost of oral anti-diabetes and 
antihypertensive drugs 
34 (87) 168 (229) -134 (-177, -93) 
    
Total cost of resource use (incl. 
medications, regardless of relation to 
diabetes) 
691 (1,058) 846 (1,066) -155 (-394, 74) 
    
3c. Intervention cost    
Total intervention cost (see Table 1) 1,137 (421) 0 (-) 1,137 (1,071, 1,205) 
GRAND TOTAL cost per participant 1,827 (1,145) 846 (1,066) 982 (732, 1,258) 
a. Included one participant in each arm who moved away from the trial participating practice. Their healthcare 
resource use was assumed to be 0 after they moved away, and their medication use was assumed to continue 
since they moved away. 
b. 95% CI values for the mean differences were obtained from the 1,000 iteration bootstrap.  
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Table 4 Cost-effectiveness results of DiRECT intervention over 1 year within trial time horizon 
 Diabetes Remission (%) (95% CIa) Mean cost (£) (95% CIa) 
Intervention 45.6 (37.9, 53.6) 1,827 (1,652, 2,021) 
Control 4.0 (1.3, 7.5) 846 (685, 1,038) 
Difference 41.6 (33.0, 50.4) 982 (732, 1,258) 
Cost per diabetes 
remission  (95% CI) 
 
2,359 (1,668, 3,250) 







Figure 1  Mean number of sachets (a) and mean number of appointments per month (b) 
offered to participants during each stage of the DiRECT intervention within year 1 (n = 149, 





Appendix 1 Unit costs for community and outpatient health-
care resource use 
Resource use item 
(unit used in the 
source) 
Unit Cost Source 
NHS community based resource use 
GP  
(per contact) 
£38·00 PSSRU 2016/17 pg. 162. Per patient contact lasting 9·22 
minutes, with qualifications 
Practice Nurse (per 
hour) 
£42·00  
(£10·85 per contact) 
PSSRU 2016/17 pg. 160. Nursing average cost per hour, 
with qualifications. 
Duration of contact per patient is 15·5 minutes (PSSRU 





(£4 per contact) 
PSSRU 2016/17 pg.159. Nurses Band 3. Average duration 
per contact is estimated to be 10min. 
Podiatrist 
(per contact) 
£41 NHS reference cost – Community health services – 




(£10·75 per contact) 
PSSRU 2016/17 pg. 153-155. Community Scientific and 
professional staff Pharmacist Band 6. Length of contact 
assumed to be 15min. 
Dietitians (per 
contact) 
£85 NHS reference cost 2016/17 community health service.A03 
dietitian £85 per contact. 
Physiotherapist 
(per contact) 
£53 NHS reference cost, AHP allied health professionals A08A1, 





£53 PSSRU 2016/17 pg. 153-155. Community Scientific and 
professional staff band 7 (£53 per hour) clinical 





£77 NHS reference cost community health service. Occupational 
therapist, adult, one to one.  
District nurse 
(per visit) 
£37 NHS reference cost – community health services. N02AF 
District Nurse, Adult, Face to face. 
Haemodialysis £137·03 NHS reference cost 2016/17 Satellite Haemodialysis or 





answered (NHS 111, 
or 999) 
£7 NHS Reference costs 2016/17 highlights, analysis and 
introduction to the data. Table 6. Costs by currency for 
ambulance services between 2014/15 and 2016/17. Unit 
cost for calls. (pg.9) 
Hear and treat or 
refer (ambulance 
trust clinician 
resolves the call or 
£37 NHS Reference costs 2016/17 highlights, analysis and 
introduction to the data. Table 6. Costs by currency for 
ambulance services between 2014/15 and 2016/17. Unit 
cost for hear and treat or refer. (pg.9) 
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refer over the 
phone) 
Ambulance service 
(see and treat or 
refer) 
£181 NHS Reference costs 2016/17 highlights, analysis and 
introduction to the data. Table 6. Costs by currency for 
ambulance services between 2014/15 and 2016/17. Unit 
cost for see and treat or refer. (pg.9) 
Ambulance (see and 
treat and convey) 
£248 NHS Reference costs 2016/17 highlights, analysis and 
introduction to the data. Table 6. Costs by currency for 
ambulance services between 2014/15 and 2016/17. Unit 
cost for see and treat and convey (pg.9) 
A&E attendance 
(per attendance)  
£148 NHS Reference costs 2016/17 highlights, analysis and 
introduction to the data. Table 2. Unit costs by point of 
delivery, 2014/15 and 2016/17 (£). Unit cost for A&E 
attendance (pg.5) 





£168 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Gynaecology £169 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Gynaecology (nurse 
led) 
£58 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Gastroenterology £226 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Gastroenterology 
(nurse led) 
£134 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Cardiology £143 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Dermatology £157 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Geriatric assessment £190 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Ear, Nose & Throat 
(ENT) 
£114 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Ophthalmology £154 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Ophthalmology 
(nurse led) 
£76 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
General medicine £255 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 






£147 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Clinical genetics £553 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Haematology £370 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
General psychiatry £233 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Orthopaedic £119 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Neurology £214 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Neurosurgery £149 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Obstetrics £181 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Clinical oncology £250 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Oral surgery & 
medicine 
£111 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Pain relief £203 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Respiratory medicine £199 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Rheumatology £214 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Urology £154 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Vascular surgery £154 ISD Scotland 2016/17 Outpatients specialty cost. R044X – 
outpatient consultant clinics, by specialty, by board. Net 
cost per attendancec 
Radiology  £65·59 ISD Scotland 2016/17 R120 Radiology services. Outpatients 
specialty cost. R044X – outpatient consultant clinics, by 
specialty, by board. Net cost per attendancec.  
Midwife service £80·98 NHS reference cost 2016/17. Total outpatient attendances 
560 midwifery service. 
Clinical microbiology £119·40 NHS reference cost 2016/17. Total outpatient attendances 
322 clinical microbiology. 
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Endocrinology £158·34 (average) 
£161·83 (consultant led) 
£110·60 (non consultant 
led) 
NHS reference cost 2016/17. Total outpatient attendances 
302 endocrinology. 
Podiatry £46·64 NHS reference cost 2016/17. Total outpatient attendances 
653 podiatry. 
Clinical immunology £263·67 NHS reference cost 2016/17. Total outpatient attendances 
316 Clinical immunology. 
Orthotics £119·07 NHS reference cost 2016/17. Total outpatient attendances. 
658 Orthotics 
Physiotherapy £48·81 NHS reference cost 2016/17. Total outpatient attendances. 
650 physiotherapy 
Out of hours GP 
service 
(per contact) 
£71·07a National Audit Office. Out of Hours GP Services in England. 
London: Department of Health and NHS England; 2014 
(https://www.nao.org.uk/wp-
content/uploads/2014/09/Out-of-hours-GP-services-in-
England1.pdf) pg 15-16. a national average cost, for opted-
out services of £68.30 in 2013-14. 
Out of hours NHS 
telephone service 
£37·00 NHS reference cost (hear and treat or refer) 
Diabetic retina 
screening 
£37·14b Scanlon PH et al. 2009/10 NHS reference cost - £33 
Walk in services £41·64b PSSRU 2009/10 pg. 119  A&E SERVICES (Weighted average 
of attendances) – walk in services leading to admitted (not 
admitted) £37(37) 





£72·83b ISD Scotland 2009/2010. R120X radiology services by board. 
Other radiology (includes ‘conventional’ X rays) net cost per 
examination: £64·71 
Ultrasonic £57·40b ISD Scotland 2009/2010. R120X radiology services by board. 
Ultrasonic net cost per examination: £51.00 
Magnetic Resonance 
Imaging 
£243·55b ISD Scotland 2009/2010. R120X radiology services by board. 
Magnetic Resonance Imaging, net cost per examination: 
£216·40  
CT scan £124·35b ISD Scotland 2009/2010. R120X radiology services by board. 




£52 NHS reference cost 2016/17 Directly accessed diagnostic 
services. EY51Z Electrocardiogram monitoring or stress 
testing. 
a. HCHS inflation factor 1.04062 (2013/14 Pay and prices index (PPI) 290.5 / 2016/17 PPI 302.3)  
b. HCHS inflation factor 1.12547 (2009/10 Pay and prices index (PPI) 268.6 / 2016/17 PPI 302.3)  
c. ISD R044X cost notes: these costs are mainly for consultation or very minor procedures, but may include patients who 
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